2013
DOI: 10.1186/1471-2407-13-378
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: BackgroundBronchial carcinoids are pulmonary neuroendocrine cell-derived tumors comprising typical (TC) and atypical (AC) malignant phenotypes. The 5-year survival rate in metastatic carcinoid, despite multiple current therapies, is 14-25%. Hence, we are testing novel therapies that can affect the proliferation and survival of bronchial carcinoids.MethodsIn vitro studies were used for the dose–response (AlamarBlue) effects of acetazolamide (AZ) and sulforaphane (SFN) on clonogenicity, serotonin-induced growth … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

6
76
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 56 publications
(82 citation statements)
references
References 59 publications
6
76
0
Order By: Relevance
“…For instance, renal cancer cell invasiveness and survival is diminished by acetazolamide in vitro [40, 41]. In addition, acetazolamide has shown anti-tumor properties in murine models [14, 42, 43]. Our data further demonstrate that acetazolamide-induced tumor growth inhibition is associated with reduced cancer cell proliferation in hypoxic zones (Figure 6A and 6B), which is in accordance with what we observe following selective knockdown of CAIX (Figure 7D).…”
Section: Discussionsupporting
confidence: 88%
“…For instance, renal cancer cell invasiveness and survival is diminished by acetazolamide in vitro [40, 41]. In addition, acetazolamide has shown anti-tumor properties in murine models [14, 42, 43]. Our data further demonstrate that acetazolamide-induced tumor growth inhibition is associated with reduced cancer cell proliferation in hypoxic zones (Figure 6A and 6B), which is in accordance with what we observe following selective knockdown of CAIX (Figure 7D).…”
Section: Discussionsupporting
confidence: 88%
“…Significant inhibitory effects were documented both in vitro and in vivo at concentrations that are non-toxic to normal bladder. The concentrations are within the clinically achievable level for AZ, already used for various other treatments [13], and close to that achievable for SFN, which is intrinsically non-toxic in these dose ranges [58]. We therefore suggest that the AZ+ SFN combination has clinical value and should be considered for trial therapy in bladder cancers with the added advantage that SFN might be effective in the chemoprevention of bladder cancer and maintenance of normal tissue health.…”
Section: Discussionsupporting
confidence: 68%
“…However, when comparing the expression of caspase-3 and PARP after SFN alone with AZ+SFN in HTB-9 cells, the expression increased by 1.5-fold only, although this was still a significant difference. Based on previous studies [13], we suggest that a longer time period for treatment would be predicted to produce greater differences.…”
Section: Az+sfn Combination Treatments Induces Apoptosis In Vitromentioning
confidence: 82%
See 1 more Smart Citation
“…Interestingly, this growth seems to be driven by 5-HT released from tumor cells. We have shown recently that inhibition of CAII in lung carcinoid cell line H727 cells maintained in vitro and in a xenograft model suppresses tumor cell proliferation and causes significant reduction in tumor mass, indicating a potential therapeutic target (22,37). This suggests that elucidating further components of the CO 2 and acid-sensing pathways may prompt the discovery of further potential therapeutic targets in the treatment of lung cancers.…”
Section: Discussionmentioning
confidence: 99%